Telomir-1

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals is advancing Telomir-1, a novel oral small molecule that functions as a metal ion regulator to extend protective telomere caps on DNA, combat oxidative stress, and address fundamental drivers of aging and chronic disease. The company has generated promising pre-clinical data in models of aging, Progeria, and Type 2 Diabetes, and is preparing for an IND submission and Phase I/II trials targeted for 2026. With a leadership team combining scientific, clinical, and financial expertise, Telomir is positioning itself in the rapidly growing longevity and age-related disease market, targeting both large prevalent conditions and high-need rare diseases.

Therapeutic Areas